<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29786181</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1724-5990</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>35</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia</Title>
                <ISOAbbreviation>G Ital Nefrol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">2018-vol3</ELocationID>
            <Abstract>
                <AbstractText>Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.</AbstractText>
                <CopyrightInformation>Copyright by SocietÃ  Italiana di Nefrologia SIN, Rome, Italy.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bellasi</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC di Nefrologia e Dialisi, Ospedale Sant'Anna, ASST-Lariana, Como.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cozzolino</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>UOC Nefrologia e Dialisi ASST Santi Paolo e Carlo, Presidio San Paolo, Milano.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malberti</LastName>
                    <ForeName>Fabio</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Struttura Complessa di Nefrologia e Dialisi Istituti Ospedalieri di Cremona.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cancarini</LastName>
                    <ForeName>Giovanni</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dipartimento della CronicitÃ , ASST, Spedali Civili e UniversitÃ  di Brescia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Esposito</LastName>
                    <ForeName>Ciro</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Struttura Complessa di Nefrologia e Dialisi Fondazione IRCCS S. Maugeri Pavia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Genderini</LastName>
                    <ForeName>Augusto</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ospedale Pubblico, Divisione di Nefrologia e Dialisi, Ospedale Caduti Bollatesi, Bollate.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guastoni</LastName>
                    <ForeName>Carlo Maria</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>UO Nefrologia ASST Ovest Milanese.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ondei</LastName>
                    <ForeName>Patrizia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>USS Emodialisi, Azienda Ospedaliera Ospedale Papa Giovanni XXIII, Bergamo.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pontoriero</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Struttura Complessa Nefrologia e Dialisi, Ospedale A Manzoni, ASST Lecco.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teatini</LastName>
                    <ForeName>Ugo</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Divisione Nefrologia e Dialisi. Ospedale Bollate.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vezzoli</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>UnitÃ  di Nefrologia e Dialisi, Istituto di Ricovero e cura a carattere scientifico San Raffaele, Milano.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Messa</LastName>
                    <ForeName>Piergiorgio</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>UnitÃ  Operativa Complessa di Nefrologia e Dialisi, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Locatelli</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ospedale &quot;Alessandro Manzoni&quot;, ASST, Lecco.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>ita</Language>
            <PublicationTypeList>
                <PublicationType UI="D017065">Practice Guideline</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>G Ital Nefrol</MedlineTA>
            <NlmUniqueID>9426434</NlmUniqueID>
            <ISSNLinking>0393-5590</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D057966">Calcimimetic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044169">Receptors, Calcium-Sensing</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1406-16-2</RegistryNumber>
                <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>72PT5993DU</RegistryNumber>
                <NameOfSubstance UI="C583569">etelcalcetide hydrochloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>UAZ6V7728S</RegistryNumber>
                <NameOfSubstance UI="D000069449">Cinacalcet</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D057966" MajorTopicYN="N">Calcimimetic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012080" MajorTopicYN="N">Chronic Kidney Disease-Mineral and Bone Disorder</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069449" MajorTopicYN="N">Cinacalcet</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006301" MajorTopicYN="N">Health Services Needs and Demand</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006934" MajorTopicYN="N">Hypercalcemia</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006962" MajorTopicYN="N">Hyperparathyroidism, Secondary</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010280" MajorTopicYN="N">Parathyroid Glands</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010281" MajorTopicYN="N">Parathyroid Hormone</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044169" MajorTopicYN="N">Receptors, Calcium-Sensing</DescriptorName>
                <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N"> CKD-MBD</Keyword>
            <Keyword MajorTopicYN="N"> cinacalcet</Keyword>
            <Keyword MajorTopicYN="N">PTH</Keyword>
            <Keyword MajorTopicYN="N">etelcalcetide</Keyword>
            <Keyword MajorTopicYN="N">secondary hyperparathyroidism</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29786181</ArticleId>
            <ArticleId IdType="pii">2018-vol3-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>